[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 10481
6. Arana-Yi C, Block AW, Sait SN, Ford LA, Barcos M, Baer MR: Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine. Leuk Res; 2008 Jul;32(7):1043-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
  • Therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/t-AML) have been reported only rarely following treatment of AML.
  • We report five patients treated for de novo AML who developed t-MDS/t-AML, all with chromosome 7 abnormalities, including -7, del(7)(q22q36) and del(7)(p11.22p22).
  • These cases further document t-MDS/t-AML as a complication of therapy for AML.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cytarabine / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / drug therapy


7. Tanaka-Harada Y, Kawakami M, Oka Y, Tsuboi A, Katagiri T, Elisseeva OA, Nishida S, Shirakata T, Hosen N, Fujiki F, Murao A, Nakajima H, Oji Y, Kanda Y, Kawase I, Sugiyama H: Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies. Cancer Sci; 2010 Mar;101(3):594-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
  • WT1 (Wilms' tumor gene 1) protein is a potent pan-tumor-associated antigen (TAA) and WT1-specific cytotoxic T lymphocytes (WT1 tetramer(+) CD8(+) T cells) are spontaneously induced in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
  • We conducted a single-cell level comparative analysis of T-cell receptor beta-chain variable region (TCR-BV) gene families of a total of 1242 spontaneously induced WT1 tetramer(+) CD8(+) T cells in HLA-A*2402(+) patients with AML or MDS and those in healthy donors (HDs).
  • This is the first report of direct usage analysis of TCR-BV gene families of individual TAA-specific CD8(+) T cells at single-cell level.
  • Usage analysis using single-cell RT-PCR of TCR-BV gene families of individual FACS-sorted WT1 tetramer(+) CD8(+) T cells showed for the first time (i) that BVs 5, 6, 20, and 27 were commonly biased in both HDs and patients;.
  • (iii) that BV19 was commonly biased in the patients; and (iv) that BVs 7 and 28, BVs 9 and 15, and BVs 12 and 29 were specifically biased in HDs, AML, and MDS patients, respectively.
  • However, statistical analysis of similarity among HD, AML, and MDS of individual usage frequencies of 24 kinds of TCR-BV gene families indicated that the usage frequencies of TCR-BV gene families in AML and MDS patients reflect those in HDs.
  • These findings represent a novel insight for a better understanding of WT1-specific immune response.
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Genes, T-Cell Receptor beta. Leukemia, Myeloid, Acute / immunology. Myelodysplastic Syndromes / immunology. WT1 Proteins / immunology


8. Cencic R, Carrier M, Trnkus A, Porco JA Jr, Minden M, Pelletier J: Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res; 2010 Apr;34(4):535-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.
  • We have previously shown that inhibition of translation initiation, using the small molecule inhibitor silvestrol, induces apoptosis in a pre-clinical murine lymphoma model when combined with daunorubicin.
  • Here we investigate the sensitivity of acute myelogenous leukemia (AML) cell lines to protein synthesis inhibition in combination with the standard cytotoxic agents daunorubicin, etoposide, and cytarabine.
  • Silvestrol shows synergy with standard-of-care agents in AML cell lines and synergizes with ABT-737, a small molecule inhibitor of Bcl-X(L) and Bcl-2.
  • The in vitro synergy between silvestrol and the cytotoxic drugs used in AML therapy provides a basis for in vivo evaluation of these combinations.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • [Cites] Annu Rev Biochem. 1999;68:913-63 [10872469.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1446-54 [19322212.001]
  • [Cites] Hematology. 2002 Feb;7(1):21-31 [12171774.001]
  • [Cites] Blood. 2003 Jan 15;101(2):425-32 [12393493.001]
  • [Cites] Genes Dev. 2003 Jun 15;17(12):1475-86 [12783855.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):889-901 [14580340.001]
  • [Cites] Nature. 2003 Dec 11;426(6967):671-6 [14668867.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4202-9 [15304385.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35217-27 [16109713.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):723-31 [16546987.001]
  • [Cites] Leuk Res. 2006 Nov;30(11):1447-51 [16704876.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2358-65 [16763210.001]
  • [Cites] Science. 2006 Oct 20;314(5798):467-71 [17053147.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):375-88 [17097560.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):389-99 [17097561.001]
  • [Cites] Cell. 2007 Jan 26;128(2):257-67 [17254965.001]
  • [Cites] PLoS One. 2007;2(2):e242 [17311107.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3509-12 [17179228.001]
  • [Cites] Blood. 2007 Aug 1;110(3):1025-8 [17426258.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2638-48 [17786246.001]
  • [Cites] Oncologist. 2007;12 Suppl 2:14-21 [18039635.001]
  • [Cites] Genes Dev. 2007 Dec 15;21(24):3232-7 [18055695.001]
  • [Cites] Curr Cancer Drug Targets. 2008 May;8(3):207-22 [18473734.001]
  • [Cites] Anticancer Drugs. 2008 Aug;19(7):705-12 [18594212.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2651-60 [18551192.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1728-36 [18548093.001]
  • [Cites] Cancer Lett. 2009 Feb 8;274(1):16-24 [18829157.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Nov;6(10):1003-16 [19176198.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Nov;6(10):1017-25 [19176199.001]
  • [Cites] PLoS One. 2009;4(4):e5223 [19401772.001]
  • [Cites] Blood. 2009 May 7;113(19):4656-66 [19190247.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1438-45 [11350915.001]
  • (PMID = 19726085.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM073855; Canada / Canadian Institutes of Health Research / / MOP-79385
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABT-737; 0 / Biphenyl Compounds; 0 / Cytotoxins; 0 / Nitrophenols; 0 / Peptide Initiation Factors; 0 / Piperazines; 0 / Protein Synthesis Inhibitors; 0 / Sulfonamides; 0 / Triterpenes; 0 / silvestrol; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS616104; NLM/ PMC4117193
  •  go-up   go-down


9. Zhou FL, Zhang WG, Wei YC, Meng S, Bai GG, Wang BY, Yang HY, Tian W, Meng X, Zhang H, Chen SP: Involvement of oxidative stress in the relapse of acute myeloid leukemia. J Biol Chem; 2010 May 14;285(20):15010-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of oxidative stress in the relapse of acute myeloid leukemia.
  • The aims of the present study were to determine the level of oxidative stress and the salient factors leading to the relapse of acute myeloid leukemia (AML).
  • Oxidative stress-related parameters and the expressions of specific genes were monitored in 102 cases of AML during a pretreatment period from a primary status to a relapse status.
  • Linear regression showed that a low T-AOC and up-regulated TRX expression were the independent factors correlated with relapse.
  • A strong association between oxidative stress and the incidence of disease relapse was observed, which has potential prognosis implications.
  • These results indicate that oxidative stress is a crucial feature of AML and probably affects the development and relapse of AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / metabolism. Oxidative Stress

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Care Med. 2009 Jul;37(7):2155-9 [19487947.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1379-86 [16923572.001]
  • [Cites] Leuk Res. 2007 Mar;31(3):387-93 [16949154.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):792-801 [17234791.001]
  • [Cites] J Pharm Pharmacol. 2007 Mar;59(3):409-17 [17331345.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12288-93 [17640917.001]
  • [Cites] Immunol Lett. 2007 Aug 15;111(2):69-75 [17644189.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2616-20 [17564752.001]
  • [Cites] Diabetes. 2008 Apr;57(4):879-88 [18003754.001]
  • [Cites] Clin Biochem. 2008 May;41(7-8):511-8 [18313403.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1221-7 [18313749.001]
  • [Cites] Acta Physiol Hung. 2008 Jun;95(2):209-18 [18642760.001]
  • [Cites] Gen Physiol Biophys. 2008 Jun;27(2):71-84 [18645221.001]
  • [Cites] Antioxid Redox Signal. 2008 Oct;10(10):1813-48 [18593226.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1685-91 [18580952.001]
  • [Cites] Pediatr Blood Cancer. 2008 Nov;51(5):613-5 [18623225.001]
  • [Cites] Biomed Environ Sci. 2008 Aug;21(4):286-9 [18837290.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Oct;295(4):C849-68 [18684987.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1969-72 [18401418.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):741-6 [18680148.001]
  • [Cites] Free Radic Biol Med. 2008 Sep 15;45(6):875-84 [18638547.001]
  • [Cites] Haematologica. 2008 Dec;93(12):1894-8 [19050070.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Feb;135(2):319-23 [18758816.001]
  • [Cites] Mol Nutr Food Res. 2009 Jan;53(1):87-103 [18979503.001]
  • [Cites] Leuk Res. 2009 Mar;33(3):490-4 [18639339.001]
  • [Cites] Zhongguo Dang Dai Er Ke Za Zhi. 2009 Feb;11(2):88-92 [19222940.001]
  • [Cites] Circ Res. 2009 Mar 27;104(6):750-7 [19179658.001]
  • [Cites] Oncologist. 2009 Mar;14(3):240-52 [19289488.001]
  • [Cites] J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009 Apr;27(2):120-39 [19412858.001]
  • [Cites] Cell Death Differ. 2009 Jun;16(6):847-57 [19247368.001]
  • [Cites] Leuk Res. 2009 Oct;33(10):1367-71 [19327827.001]
  • [Cites] Leuk Res. 2009 Oct;33(10):1297 [19560202.001]
  • [Cites] Nephron Clin Pract. 2009;112(4):c255-61 [19546585.001]
  • [Cites] Int J Neuropsychopharmacol. 2009 Sep;12(8):1089-96 [19272208.001]
  • [Cites] Environ Toxicol. 2009 Oct;24(5):446-52 [18979530.001]
  • [Cites] Cancer Biol Ther. 2009 Jul;8(14):1402-8 [19597340.001]
  • [Cites] Yonsei Med J. 2009 Oct 31;50(5):677-82 [19881972.001]
  • [Cites] J Mol Endocrinol. 2009 Dec;43(6):251-61 [19620238.001]
  • [Cites] Leuk Res. 2000 Jun;24(6):461-8 [10781678.001]
  • [Cites] Free Radic Biol Med. 2001 Jun 1;30(11):1286-92 [11368926.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):41-5 [15158439.001]
  • [Cites] J Clin Lab Anal. 1992;6(1):47-53 [1542083.001]
  • [Cites] Mol Cell Biochem. 2004 Nov;266(1-2):37-56 [15646026.001]
  • [Cites] Clin Chem Lab Med. 2005;43(3):294-7 [15843234.001]
  • [Cites] Drug Resist Updat. 2005 Oct;8(5):322-30 [16230045.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • [Cites] Perit Dial Int. 2006 Mar-Apr;26(2):207-12 [16623427.001]
  • [Cites] Toxicology. 2007 Jan 5;229(1-2):1-10 [17118505.001]
  • (PMID = 20233720.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; EC 1.17.3.2 / Xanthine Oxidase; EC 1.4.3.4 / Monoamine Oxidase; EC 3.5.4.4 / Adenosine Deaminase
  • [Other-IDs] NLM/ PMC2865279
  •  go-up   go-down


10. Schoonmaker JP, Trenkle AH, Beitz DC: Effect of feeding wet distillers grains on performance, marbling deposition, and fatty acid content of beef from steers fed low- or high-forage diets. J Anim Sci; 2010 Nov;88(11):3657-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Steers fed a low-forage diet gained BW faster (P < 0.001) than did steers fed a high-forage diet; the amount of WDG fed did not affect (P = 0.25) daily BW gain.
  • Longissimus muscle area (P = 0.08) and yield grade (P < 0.01) were greater for steers fed low-forage diets compared with steers fed high-forage diets.
  • Longissimus muscle area (P = 0.02) and yield grade (P = 0.03) increased as WDG concentration increased.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601523.001).
  • [ISSN] 1525-3163
  • [Journal-full-title] Journal of animal science
  • [ISO-abbreviation] J. Anim. Sci.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids
  •  go-up   go-down


11. Ryningen A, Wergeland L, Glenjen N, Gjertsen BT, Bruserud O: In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leuk Res; 2005 Feb;29(2):185-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8.
  • Interactions between native human acute myelogenous leukemia (AML) blasts and nonleukemic cells in the bone marrow microenvironment seem important both for disease development chemosensitivity.
  • Native human AML blasts from consecutive patients were cultured with normal human bone marrow stromal cells and two fibroblast lines (HFL1 and Hs27) separated by a semipermeable membrane.
  • This bidirectional crosstalk via the cytokine network between AML blasts and fibroblasts caused (i) increased proliferation, (ii) mediated antiapoptotic signalling and (iii) increased local levels of proangiogenic IL8.
  • [MeSH-major] Cell Communication. Cytokines / physiology. Fibroblasts / physiology. Interleukin-8 / biosynthesis. Leukemia, Myeloid, Acute / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / physiology. Cell Line, Tumor. Cell Proliferation. Coculture Techniques. Disease Progression. Female. Humans. Male. Middle Aged. Signal Transduction. Stromal Cells / physiology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607368.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-8
  •  go-up   go-down


12. Martins C, Lacerda JF, Lourenço F, Carmo JA, Lacerda JM: Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience. Acta Med Port; 2005 Sep-Oct;18(5):329-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
  • We report our results of autologous stem cell transplantation (SCT) in patients with AML during the last 13 years.
  • Between August 1990 and December 2003, 42 patients with acute myeloid leukemia (AML) received an autologous SCT.
  • Patients were classified as standard risk if first complete remission (CR) was induced after one or two chemotherapy regimens and the white blood cell count at presentation was below 50,000/mL (n=12), while patients requiring more than two induction regimens to attain first CR and with CR2 ou more advanced disease and/or had a higher white blood cell count at presentation were defined as high risk (n=30).
  • The median patient age was 24 years (range, 2-56 years), and the median time interval from diagnosis to autologous SCT was 9 months (range 3-87 months).
  • The conditioning regimen for SCT consisted of busulfan (BU) 16 mg/kg and melfalan (MEL) 180 mg/m2 (BUMEL) in 17 (40%) patients and busulfan 16 mg/kg and VP-16 60 mg/kg (BUVP16) in 22 (52%) patients.
  • Three patients received a different conditioning regimen with BCNU 300 mg/m2, VP16 2 g/m2 and melphalan 160 mg/m2 (BEM).
  • Patients with FAB M3 subtype also had a superior OS than the other FAB subtypes (100% vs 44%, p=0.05).
  • In fact, the patients with standard risk had a superior OS and DFS than those with high risk disease (67% vs 23%, p=0.0004; and 50% vs 27%, p=0.01, respectively).
  • When patients with FAB M3 disease were excluded from the analysis, the group with standard risk continue to have a superior OS and DFS (67% vs 13%, p=0.008; and 50% vs 14%, p=0.02, respectively).
  • We conclude that autologous SCT is an effective treatment in AML with the possibility of long survivorship, particularly in patients with standard risk disease.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Transplantation Conditioning / methods. Transplantation, Autologous. Treatment Outcome


13. Neumann F, Gattermann N, Barthelmes HU, Haas R, Germing U: Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia. Leuk Res; 2009 Feb;33(2):232-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.
  • The risk of AML evolution was higher in patients with B2M> or =2mg/dl.
  • Using multivariate analysis we found the B2M level at the time of diagnosis to be an independent prognostic parameter for survival and for the risk of developing AML in high-risk MDS patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Myelodysplastic Syndromes / diagnosis. beta 2-Microglobulin / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Young Adult


1
Advertisement
4. Bunin NJ, Davies SM, Aplenc R, Camitta BM, DeSantes KB, Goyal RK, Kapoor N, Kernan NA, Rosenthal J, Smith FO, Eapen M: Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. J Clin Oncol; 2008 Sep 10;26(26):4326-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy.
  • PURPOSE: Identify prognostic factors that influence outcome after unrelated donor bone marrow transplantation in children with acute myeloid leukemia (AML).
  • PATIENTS AND METHODS: Included are 268 patients (age <or= 18 years) with AML in second complete remission (n = 142), relapse (n = 90), or primary induction failure (n = 36) at transplantation.
  • RESULTS: In this analysis, the only risk factor that predicted leukemia recurrence and overall and leukemia-free survival was disease status at transplantation.
  • The 5-year probabilities of leukemia-free survival were 45%, 20%, and 12% for patients who underwent transplantation at second complete remission, relapse, and primary induction failure, respectively.
  • As expected, risk of acute but not chronic graft-versus-host disease (GVHD) was lower with T-cell-depleted bone marrow grafts; T-cell-depleted grafts were not associated with higher risks of leukemia recurrence.
  • We observed similar risks of leukemia relapse in patients with and without acute and chronic GVHD.
  • CONCLUSION: Children who underwent transplantation in remission had a superior outcome compared with children who underwent transplantation during relapse or persistent disease.
  • Nevertheless, 20% of children who underwent transplantation in relapse are long-term survivors, suggesting that unrelated donor bone marrow transplantation is an effective therapy in a significant proportion of children with recurrent or primary refractory AML.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1999 Oct;13(5):1091-112, viii-ix [10553263.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4576-83 [17785583.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1611-9 [12393725.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2940-7 [12885813.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4377-85 [14645428.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1534-8 [9766496.001]
  • [Cites] Leukemia. 1999 Jan;13(1):25-31 [10049056.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Lancet. 2005 Aug 27-Sep 2;366(9487):733-41 [16125590.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2101-16 [16136167.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2054-62 [16136168.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2125-9 [16281077.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2030-42 [16304570.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9172-8 [16361619.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):157-63 [17133407.001]
  • [Cites] Lancet. 2007 Jun 9;369(9577):1947-54 [17560447.001]
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • (PMID = 18779619.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2653120
  •  go-up   go-down


15. Metzner A, Precht C, Fehse B, Fiedler W, Stocking C, Günther A, Mayr GW, Jücker M: Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D. Gene Ther; 2009 Apr;16(4):570-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D.
  • Acute myeloid leukemia (AML) is a malignant disease characterized by deregulated proliferation of immature myeloid cells.
  • Constitutive activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently detected in approximately 50-70% of AML patients.
  • After lentiviral-mediated gene transfer of INPP5D into CD34(+) cells derived from AML patients (n=12) the granulocyte macrophage-colony stimulating factor (GM-CSF)-dependent proliferation was reduced in all samples analyzed (average 86%; range 72-93%).
  • In addition, SHIP1 reduced the autonomous proliferation of CD34(+) cells from a patient with a secondary AML who had a very high peripheral blast count (300 x 10(9) l(-1)).
  • These data show that SHIP1 can effectively block GM-CSF-dependent and autonomous proliferation of AML cells.
  • [MeSH-major] Antigens, CD34 / blood. Leukemia, Myeloid, Acute / pathology. Phosphoric Monoester Hydrolases / genetics
  • [MeSH-minor] Cell Proliferation / drug effects. Gene Transfer Techniques. Genetic Vectors. Humans. Lentivirus / genetics. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Ribonucleosides / pharmacology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148132.001).
  • [ISSN] 1476-5462
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Ribonucleosides; 2421HMY9N6 / triciribine; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.56 / inositol-polyphosphate 5-phosphatase
  •  go-up   go-down


16. Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S: Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev; 2008 Feb;34(1):49-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
  • Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti-CD33 antibody (hP67.6) linked to N-acetyl-calicheamicin 1,2-dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic.
  • GO was approved conditionally by the Federal Drug Administration in May 2000 as single-agent therapy for first recurrence of acute myeloid leukemia (AML) in patients over the age of 60 years who are unfit for conventional cytotoxic therapy.
  • GO monotherapy at the dose of 9 mg/m(2) is complicated with hepatic veno-occlusive disease in approximately 5% of cases, particularly prior to or following stem cell transplantation.
  • GO has shown remarkable activity in acute promyelocytic leukemia, particularly for the elimination of minimal residual disease.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Humans. Leukemia, Promyelocytic, Acute / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942233.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / gemtuzumab
  • [Number-of-references] 77
  •  go-up   go-down


17. Trafalis DT, Poulakidas E, Kapsimali V, Tsigris C, Papanicolaou X, Harhalakis N, Nikiforakis E, Mentzikof-Mitsouli C: Platelet production and related pathophysiology in acute myelogenous leukemia at first diagnosis: prognostic implications. Oncol Rep; 2008 Apr;19(4):1021-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet production and related pathophysiology in acute myelogenous leukemia at first diagnosis: prognostic implications.
  • Among various laboratory and clinical features megakaryocytopoiesis and platelet (PLT) counts have been previously insufficiently evaluated for their prognostic significance in acute myelogenous leukaemia (AML).
  • We studied several clinical and laboratory features of 108 first diagnosed AML patients in relation with their prognosis.
  • This study focused on the prognostic impact of PLT counts and related molecular biology in AML patients at initial diagnosis.
  • In particular, the PLT counts were correlated with the endogenous production of thrombopoietin (TPO), c-mpl expression, CD34+ leukemic blast cell proportion, cytogenetics, and a prognostic correlation was established.
  • We found that the most favorable prognosis appeared in the AML patient group with PLTs <25x10(9)/l and correlated to cytogenetic findings (normal or abnormal karyotypes), while by far the most unfavorable prognosis was found in the patient group with PLTs > or =130x10(9)/l independent of the corresponding cytogenetics.
  • It was demonstrated that AML patients with normal or elevated PLT counts at first presentation, may constitute a distinct patient group with particular characteristics such as higher levels of endogenous TPO production, high expression of CD34+ leukemic blast cells, higher expression of c-mpl and consequently low response to chemotherapy and a very poor prognosis.
  • These correlations between PLTs production (megakaryothrombopoiesis), TPO serum levels and TPO receptor (c-mpl) expression may help in the determination of risk-adapted AML patient groups and of targeted therapeutic strategies.
  • [MeSH-major] Blood Platelets / physiology. Leukemia, Myeloid, Acute / blood


18. Patel VB, Singh R, Connolly C, Kasprowicz V, Zumla A, Ndungu T, Dheda K: Comparison of a clinical prediction rule and a LAM antigen-detection assay for the rapid diagnosis of TBM in a high HIV prevalence setting. PLoS One; 2010 Dec 22;5(12):e15664
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of a clinical prediction rule and a LAM antigen-detection assay for the rapid diagnosis of TBM in a high HIV prevalence setting.
  • BACKGROUND/OBJECTIVE: The diagnosis of tuberculous meningitis (TBM) in resource poor TB endemic environments is challenging.
  • The accuracy of current tools for the rapid diagnosis of TBM is suboptimal.
  • We sought to develop a clinical-prediction rule for the diagnosis of TBM in a high HIV prevalence setting, and to compare performance outcomes to conventional diagnostic modalities and a novel lipoarabinomannan (LAM) antigen detection test (Clearview-TB®) using cerebrospinal fluid (CSF).
  • METHODS: Patients with suspected TBM were classified as definite-TBM (CSF culture or PCR positive), probable-TBM and non-TBM.
  • There were 39, 55 and 54 patients in the definite, probable and non-TBM groups, respectively.
  • The LAM sensitivity and specificity (95%CI) was 31% (17;48) and 94% (85;99), respectively (cut-point ≥ 0.18).
  • LAM positivity was associated with HIV co-infection and low CD4 T cell count (CD4<200 vs. >200 cells/µl; p = 0.03).
  • When LAM was combined with the clinical-prediction-rule, the sensitivity increased significantly (p<0.001) to 63% (47;68) and specificity remained high at 93% (82;98).
  • CONCLUSIONS: Despite its modest sensitivity the LAM ELISA is an accurate rapid rule-in test for TBM that has incremental value over smear-microscopy.
  • The rule-in value of LAM can be further increased by combination with a clinical-prediction rule, thus enhancing the rapid diagnosis of TBM in HIV-infected persons with advanced immunosuppression.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect. 2009 Sep;59(3):167-87 [19643501.001]
  • [Cites] Scand J Infect Dis. 2009;41(3):188-94 [19235095.001]
  • [Cites] Infection. 2009 Dec;37(6):508-13 [19669088.001]
  • [Cites] AIDS. 2009 Sep 10;23(14):1875-80 [20108382.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):145-51 [19692904.001]
  • [Cites] PLoS One. 2010;5(3):e9848 [20352098.001]
  • [Cites] Curr Opin Pulm Med. 2010 May;16(3):262-70 [20375787.001]
  • [Cites] J Clin Microbiol. 2010 Aug;48(8):2972-4 [20534796.001]
  • [Cites] Am J Respir Crit Care Med. 2010 Aug 15;182(4):569-77 [20442433.001]
  • [Cites] Lancet Infect Dis. 2010 Nov;10(11):803-12 [20822958.001]
  • [Cites] Acta Neurol Scand. 2000 Jan;101(1):61-4 [10660155.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):289-99 [10675209.001]
  • [Cites] Am J Respir Crit Care Med. 2000 May;161(5):1713-9 [10806179.001]
  • [Cites] J Neuroimmunol. 2000 Nov 1;111(1-2):10-4 [11063816.001]
  • [Cites] J Microbiol Methods. 2001 May;45(1):41-52 [11295196.001]
  • [Cites] Scand J Infect Dis. 2001;33(4):279-84 [11345220.001]
  • [Cites] Clin Diagn Lab Immunol. 2002 Mar;9(2):344-7 [11874875.001]
  • [Cites] Clin Chest Med. 2002 Jun;23(2):351-4 [12092030.001]
  • [Cites] Lancet. 2002 Oct 26;360(9342):1287-92 [12414204.001]
  • [Cites] Lancet Infect Dis. 2003 Oct;3(10):633-43 [14522262.001]
  • [Cites] J Clin Microbiol. 2004 Jan;42(1):378-9 [14715783.001]
  • [Cites] JAMA. 1979 Jan 19;241(3):264-8 [102806.001]
  • [Cites] Acta Cytol. 1982 Sep-Oct;26(5):678-80 [6959457.001]
  • [Cites] J Hyg (Lond). 1986 Apr;96(2):231-8 [3084628.001]
  • [Cites] Medicine (Baltimore). 1987 Jul;66(4):317-26 [3600257.001]
  • [Cites] Infect Immun. 1991 May;59(5):1755-61 [1850379.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):668-72 [1346547.001]
  • [Cites] Am J Med. 1992 Nov;93(5):520-4 [1442854.001]
  • [Cites] Arch Intern Med. 1996 Aug 12-26;156(15):1710-6 [8694670.001]
  • [Cites] Clin Infect Dis. 1996 Jun;22(6):982-8 [8783697.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Oct;81(1):35-40 [8808639.001]
  • [Cites] Am J Med Sci. 1997 Jun;313(6):325-31 [9186145.001]
  • [Cites] Am J Trop Med Hyg. 1998 Jan;58(1):28-34 [9452288.001]
  • [Cites] QJM. 1998 Nov;91(11):743-7 [10024937.001]
  • [Cites] Neurol Clin. 1999 Nov;17(4):737-59 [10517926.001]
  • [Cites] J Clin Pathol. 1953 Aug;6(3):241-2 [13084774.001]
  • [Cites] J Infect Dis. 2005 Jan 15;191(2):234-7 [15609233.001]
  • [Cites] Epidemiology. 2005 Jan;16(1):73-81 [15613948.001]
  • [Cites] J Infect Dis. 2005 Dec 15;192(12):2134-41 [16288379.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):2007-14 [16424233.001]
  • [Cites] Int J Tuberc Lung Dis. 2006 Jan;10(1):99-103 [16466045.001]
  • [Cites] J Clin Microbiol. 2006 Sep;44(9):3160-6 [16954242.001]
  • [Cites] Int J Infect Dis. 2007 Jul;11(4):348-54 [17321183.001]
  • [Cites] Thorax. 2007 Oct;62(10):911-8 [17675320.001]
  • [Cites] Clin Microbiol Rev. 2008 Apr;21(2):243-61, table of contents [18400795.001]
  • [Cites] Int J Tuberc Lung Dis. 2009 Oct;13(10):1253-9 [19793430.001]
  • (PMID = 21203513.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / D43 TW000231; United States / FIC NIH HHS / TW / D43TW00231
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Lipopolysaccharides; 0 / lipoarabinomannan
  • [Other-IDs] NLM/ PMC3008727
  •  go-up   go-down


19. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K: Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood; 2005 Feb 15;105(4):1768-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
  • Present studies show that LBH589, a novel cinnamic hydroxamic acid analog histone deacetylase inhibitor, induces acetylation of histone H3 and H4 and of heat shock protein 90 (hsp90), increases p21 levels, as well as induces cell-cycle G(1) phase accumulation and apoptosis of the human chronic myeloid leukemia blast crisis (CML-BC) K562 cells and acute leukemia MV4-11 cells with the activating length mutation of FLT-3.
  • In the imatinib mesylate (IM)-refractory leukemia cells expressing Bcr-Abl with the T315I mutation, treatment with the combination attenuated the levels of the mutant Bcr-Abl and induced apoptosis.
  • Finally, cotreatment with LBH589 and 17-AAG also induced more apoptosis of IM-resistant primary CML-BC and acute myeloid leukemia (AML) cells (with activating mutation of FLT-3) than treatment with either agent alone.
  • [MeSH-major] Blast Crisis / metabolism. Enzyme Inhibitors / pharmacology. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Histone Deacetylase Inhibitors. Hydroxamic Acids / analogs & derivatives. Hydroxamic Acids / pharmacology. Leukemia, Myeloid / metabolism. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics. Rifabutin / analogs & derivatives. Rifabutin / pharmacology
  • [MeSH-minor] Acute Disease. Apoptosis / drug effects. Benzamides. Benzoquinones. Cell Line, Tumor. Drug Combinations. Drug Synergism. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / genetics. Fusion Proteins, bcr-abl / metabolism. Gene Deletion. Gene Expression Regulation. Humans. Imatinib Mesylate. Indoles. K562 Cells. Lactams, Macrocyclic. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Piperazines / pharmacology. Point Mutation. Polyubiquitin / metabolism. Proteasome Endopeptidase Complex / metabolism. Pyrimidines / pharmacology. fms-Like Tyrosine Kinase 3

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. RIFABUTIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15514006.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA95188
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Benzoquinones; 0 / Drug Combinations; 0 / Enzyme Inhibitors; 0 / HSP90 Heat-Shock Proteins; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Indoles; 0 / Lactams, Macrocyclic; 0 / Piperazines; 0 / Proto-Oncogene Proteins; 0 / Pyrimidines; 120904-94-1 / Polyubiquitin; 1W306TDA6S / Rifabutin; 4GY0AVT3L4 / tanespimycin; 8A1O1M485B / Imatinib Mesylate; 9647FM7Y3Z / panobinostat; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


20. Hampson P, Wang K, Milverton L, Ersvaer E, Bruserud O, Lord JM: Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005). Apoptosis; 2010 Aug;15(8):946-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005).
  • The novel small molecule ingenol 3-angelate (PEP005) has been shown previously to induce apoptosis in leukaemic cell lines and primary AML cells, an effect that requires the expression of protein kinase C-delta (PKCdelta).
  • Here we have investigated signalling events downstream of PKCdelta that determine sensitivity of AML cells to PEP005.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Diterpenes / pharmacology. Leukemia, Myeloid, Acute / metabolism. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467815.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / 3-ingenyl angelate; 0 / Antineoplastic Agents; 0 / Diterpenes; 0 / Enzyme Inhibitors; 0 / Flavonoids; EC 2.7.11.13 / Protein Kinase C-delta; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


21. Meshinchi S, Arceci RJ: Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist; 2007 Mar;12(3):341-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
  • Acute myeloid leukemia (AML) has posed significant therapeutic challenges to pediatric oncologists.
  • Despite intensive therapy, half of the children with AML relapse and die from their disease.
  • Efforts to identify risk factors in AML are directed toward defining populations who may benefit from alternative therapies.
  • Patients at lower risk for relapse may benefit from treatment de-escalation, sparing them adverse side effects.
  • Management of high-risk patients may prove more difficult, as the nearly myeloablative nature of AML therapy leaves little room for therapy escalation short of stem cell transplantation.
  • This review evaluates prognostic factors in pediatric AML and discusses the feasibility of using these factors in risk-adapted therapy regimens.
  • [MeSH-major] Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / therapeutic use. Child. Humans. Neoplasm Recurrence, Local. Prognosis. Risk Assessment. Risk Factors. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405900.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 133
  •  go-up   go-down


22. Fuh B, Lurito J, Grossi M, Daeschner C, Russo S: Bilateral internal carotid artery occlusions in a pediatric patient with refractory acute myeloid leukemia. Pediatr Blood Cancer; 2010 May;54(5):770-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral internal carotid artery occlusions in a pediatric patient with refractory acute myeloid leukemia.
  • Thromboembolism is a well-known complication of cancer including acute myeloid leukemia (AML) especially in patients with high myeloblast counts.
  • We report the case of a 3-year-old male with refractory AML who developed spontaneous bilateral internal carotid artery occlusion with diffuse cerebral infarcts.
  • [MeSH-major] Carotid Artery, Internal. Carotid Stenosis / etiology. Cerebral Infarction / etiology. Leukemia, Myeloid, Acute / complications

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20052773.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Rabbat A, Chaoui D, Montani D, Legrand O, Lefebvre A, Rio B, Roche N, Lorut C, Marie JP, Huchon G: Prognosis of patients with acute myeloid leukaemia admitted to intensive care. Br J Haematol; 2005 May;129(3):350-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of patients with acute myeloid leukaemia admitted to intensive care.
  • This retrospective study assessed the prognostic factors associated with early and long-term outcome in consecutive patients with acute myeloid leukaemia (AML) admitted to the intensive care unit (ICU) over a 9-year period.
  • For 68%, admission occurred within the first month following diagnosis of AML.
  • The main reason for ICU admission was an acute respiratory disease in 82% of cases.
  • Factors significantly associated with in-ICU death in multivariate analysis were simplified acute physiology score II and need for invasive MV (IMV).
  • Age, performance status, AML3 subtype and complete remission were significantly associated with 1-year survival.
  • Patients with acute respiratory failure initially supported with non-invasive MV had significantly better ICU outcome than patients initially supported with IMV.
  • In conclusion, ICU admission is justified for selected patients with AML.
  • The ICU mortality rate is highly predictable by the acute illness severity score.
  • [MeSH-major] Critical Care. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Female. Hospital Mortality. Humans. Male. Middle Aged. Prognosis. Respiration, Artificial. Respiratory Insufficiency / etiology. Retrospective Studies. Risk Factors. Severity of Illness Index. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Critical Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842658.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Tseng MY, Chen YC, Lin YY, Chu SJ, Tsai SH: Simultaneous bilateral central retinal vein occlusion as the initial presentation of acute myeloid leukemia. Am J Med Sci; 2010 Apr;339(4):387-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous bilateral central retinal vein occlusion as the initial presentation of acute myeloid leukemia.
  • Ocular involvement is not uncommon in patients with leukemia; however, bilateral CRVO as a complication of acute myeloid leukemia has rarely been reported.
  • Here, we report a patient who had simultaneous bilateral CRVO as the initial presentation of acute myeloid leukemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis. Retinal Vein Occlusion / complications. Retinal Vein Occlusion / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20186040.001).
  • [ISSN] 1538-2990
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


25. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer; 2007 Mar 15;109(6):1114-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
  • BACKGROUND: The survival of older patients with acute myeloid leukemia has not improved.
  • Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach.
  • METHODS: Between December 1998 and November 2003, as part of National Cancer Research Institute Acute Myeloid Leukemia 14 Trial, 217 patients, who were deemed unfit for intensive chemotherapy were randomized to receive low-dose cytarabine (Ara-C) (20 mg twice daily for 10 days) or hydroxyurea with or without all-trans retinoic acid (ATRA).
  • Patients who had adverse cytogenetics did not benefit.
  • Toxicity scores or supportive care requirements did not differ between the treatment arms.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Acute Disease. Aged. Cytarabine / administration & dosage. Cytarabine / adverse effects. Female. Humans. Hydroxyurea / administration & dosage. Hydroxyurea / adverse effects. Male. Middle Aged. Risk. Survival. Treatment Outcome. Tretinoin / administration & dosage. Tretinoin / adverse effects


26. Sino-US Shanghai Leukemia Cooperative Group: [Distribution of WHO subtypes, initial treatment outcomes and prognosis study of 623 unselected adult patients with acute myeloid leukaemia in Shanghai.]. Zhonghua Xue Ye Xue Za Zhi; 2010 Feb;31(2):102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distribution of WHO subtypes, initial treatment outcomes and prognosis study of 623 unselected adult patients with acute myeloid leukaemia in Shanghai.].
  • OBJECTIVE: To investigate the current status of acute myeloid leukemia (AML) treatment in Shanghai.
  • METHODS: From 2003 to 2007, a total of successive 623 patients with adult AML were diagnosed and classified according to WHO criteria.
  • Multilineage dysplasia in de novo AML was not an independent prognostic factor after adjusted by cytogenetics, age and WBC count.
  • CONCLUSIONS: The CR rate and survival of AML were improved in the past 20 years.
  • The short-term treatment outcome of AML was comparable to that in developed countries, while the long-term one was worse.
  • [MeSH-minor] Adult. China. Humans. Leukemia, Myeloid, Acute / drug therapy. Prognosis. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302797.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine
  • [Investigator] Wang XQ
  •  go-up   go-down


27. Sahu GR, Mishra R, Nagpal JK, Das BR: Notice of retraction. Alteration of p73 in acute myelogenous leukemia. Am J Hematol; 2008 Aug;83(8):691
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notice of retraction. Alteration of p73 in acute myelogenous leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionOf] Sahu GR, Mishra R, Nagpal JK, Das BR. Am J Hematol. 2005 May;79(1):1-7 [15849769.001]
  • (PMID = 18615454.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Retraction of Publication
  • [Publication-country] United States
  •  go-up   go-down


28. Cellai C, Laurenzana A, Bianchi E, Sdelci S, Manfredini R, Vannucchi AM, Caporale R, Balliu M, Mannelli F, Ferrari S, Bosi A, Miniati D, Cocco PL, Veronneau S, Stankova J, Paoletti F: Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Exp Hematol; 2009 Oct;37(10):1176-1185.e21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN.
  • OBJECTIVE: This study aimed to investigate the mechanisms of action of WEB-2170, an inverse agonist of platelet-activating factor receptor, capable of inducing apoptosis in human acute myelogenous leukemia (AML) cells.
  • MATERIAL AND METHODS: Gene expression profiling followed by cytofluorimetric, morphologic, and biologic analyses were used to monitor WEB-2170 effects in AML cell lines (ie, NB4, KG1, NB4-MR4, THP1, and U937) and blasts from patients with different AML (M0-M5) subtypes.
  • We have found that WEB-2170 triggered apoptosis in NB4, KG1, and NB4-MR4 cells where PTEN was expressed, but not in THP1 and U937 cells where PTEN was absent.
  • CONCLUSION: We demonstrated that WEB-2170 is a powerful antileukemic agent with interesting translational opportunities to treat AML and described mechanisms of drug-induced intrinsic and extrinsic apoptosis both in AML cell lines and blasts from AML patients by addressing PTEN as the master regulator of the whole process.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Azepines / pharmacology. Leukemia, Myeloid / pathology. Neoplasm Proteins / physiology. PTEN Phosphohydrolase / physiology. Triazoles / pharmacology
  • [MeSH-minor] Acute Disease. Adult. Aged. Cell Line, Tumor / drug effects. Female. G0 Phase / drug effects. Gene Expression Profiling. Gene Expression Regulation, Leukemic / drug effects. Gene Expression Regulation, Leukemic / physiology. Humans. Male. Middle Aged. Neoplastic Stem Cells / drug effects. Neoplastic Stem Cells / pathology. Phosphorylation / drug effects. Polymerase Chain Reaction. Protein Processing, Post-Translational / drug effects. Protein Transport / drug effects. RNA Interference. RNA, Small Interfering / pharmacology. Young Adult


29. Montesinos JJ, Sánchez-Valle E, Flores-Figueroa E, Martínez-Jaramillo G, Flores-Guzmán P, Miranda-Peralta E, Gutiérrez-Romero M, Mayani H: Deficient proliferation and expansion in vitro of two bone marrow cell populations from patients with acute myeloid leukemia in response to hematopoietic cytokines. Leuk Lymphoma; 2006 Jul;47(7):1379-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficient proliferation and expansion in vitro of two bone marrow cell populations from patients with acute myeloid leukemia in response to hematopoietic cytokines.
  • One has previously characterized two different hematopoietic cell populations (obtained by negative-selection) from normal bone marrow.
  • One has also characterized the chronic myeloid leukemia (CML) counterparts of these two populations and demonstrated functional deficiencies in terms of their growth in culture.
  • In keeping with this line of research, the goal of the present study was to obtain the same two populations (Populations I and II) from acute myeloid leukemia (AML) bone marrow and to characterize their biological behavior under the same culture conditions.
  • The results demonstrated that AML-derived Populations I and II were unable to proliferate in culture conditions that allowed significant proliferation of Populations I and II from normal marrow.
  • Population I from AML also showed a deficient expansion capacity; in contrast, Population II cells were able to expand to a similar extent to the one observed for Population II from normal marrow.
  • Both normal and AML populations were highly sensitive to the inhibitory effects of TNF-alpha; interestingly, whereas in normal fractions TNF-alpha showed a more pronounced inhibitory effect on more mature cells (Population I), this cytokine inhibited proliferation and expansion of AML Populations I and II in a similar degree.
  • It is noteworthy that the functional deficiencies observed in AML cells were even more pronounced than those previously reported for cultures of CML cells.
  • [MeSH-major] Bone Marrow / metabolism. Bone Marrow Cells / cytology. Bone Marrow Cells / metabolism. Cytokines / metabolism. Leukemia, Myeloid, Acute / metabolism
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / biosynthesis. Antigens, CD38 / biosynthesis. Cell Culture Techniques / methods. Cell Proliferation. Culture Media, Serum-Free. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Male. Middle Aged. Stem Cells / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923572.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Culture Media, Serum-Free; 0 / Cytokines; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


30. Ruan GR, Li JL, Qin YZ, Li LD, Xie M, Chang Y, Zhang Y, Liu YR, Jiang B, Chen SS, Huang XJ: Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia. Ann Hematol; 2009 Feb;88(2):159-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia.
  • Recently, mutations in the nucleophosmin (NPM1) gene were detected in 50-60% of adult acute myelogenous leukemia (AML) patients, mainly with a normal karyotype.
  • In this study, we detected typical NPM1 mutations (types A, B, D) in untreated Chinese AML patients using real-time quantitative polymerase chain reaction (RQ-PCR) followed by sequence analysis.
  • The detection rate of NPM1 mutations in 220 AML patients was 16.4%, including 107 (14.2%) with the French-American-British (FAB) subtype M2, 43 (2.3%) with M3, and 52 (30.8%) with M4/M5.
  • Only one case each with an NPM1 mutation was detected in four M0, seven M1, five M6, and two M7 cases.
  • Further, 38.9% (14/36) patients with NPM1 mutations simultaneously exhibited internal tandem duplications in the FLT3 gene, and 66.7% (22/33) patients did not express CD34.
  • The results demonstrated that RQ-PCR was a reliable and sensitive method for detecting NPM1 mutations, for screening AML, and for the quantitative analysis of minimal residual diseases.
  • [MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics


31. Venizelos ID, Klonizakis I, Vlahaki E, Haralambidou S, Tatsiou Z, Ioannidou E: Skin relapse of acute myeloid leukemia associated with trisomy 8. Acta Dermatovenerol Alp Pannonica Adriat; 2007 Jun;16(2):77-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin relapse of acute myeloid leukemia associated with trisomy 8.
  • Acute myeloid leukemia (AML) is a morphologically diverse group of hematopoietic malignancies characterized by proliferation of immature cells that arise in the myeloid progenitor cells of the bone marrow.
  • It shows cutaneous lesions relatively rarely.
  • An association of AML with skin involvement and trisomy 8 has rarely been reported.
  • We present the case of a 74-year-old woman that presented with fatigue, nausea, dyspnea, and night sweats.
  • Accordingly, a diagnosis of AML involving the skin was made.
  • [MeSH-major] Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / pathology. Skin Neoplasms / pathology. Trisomy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992463.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovenia
  •  go-up   go-down


32. Aref S, El-Sherbiny M, Azmy E, Goda T, Selim T, El-Refaie M, Emaad T: Elevated serum endostatin levels is associated with favorable outcome in acute myeloid leukemia. Indian J Hematol Blood Transfus; 2008 Mar;24(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated serum endostatin levels is associated with favorable outcome in acute myeloid leukemia.
  • The levels and the prognostic relevance of serum endostatin in AML patient is not fully clear.
  • AIM: To evaluate serum levels of endostatin in acute myeloid leukemia patients before chemotherapy and after achieving complete remission and to correlate endostatin levels with patients outcome.
  • MATERIALS AND METHODS: Serum samples from 30 adult patients (22 males and 8 females, median age 37, range 19-66 years) with AML had been taken before chemotherapy was administered.
  • RESULTS: Endostatin serum levels were not significantly different in the pretreatment AML patients as compared to that in normal controls (P>0.05).
  • In AML patients the baseline endostatin levels were significantly lower than at CR (P=0.001).
  • No significant correlation were detected between pretreatment serum endostatin levels and age, peripheral blood white cell counts, platelet counts, bone marrow blast cell counts, blast cell distribution ratio.
  • The prognostic value of sE was also evaluated by dividing AML patients into high and low sE groups using the 75 percentile sE levels of the patients group as cutoff.
  • CONCLUSIONS: Elevated endostatin levels at AML diagnosis is a good prognostic marker for patients' outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] J Biol Chem. 1998 Sep 25;273(39):25404-12 [9738008.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11721-6 [10206987.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):504-9 [10460612.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3717-21 [10572084.001]
  • [Cites] Blood. 2000 Jan 1;95(1):309-13 [10607717.001]
  • [Cites] EMBO J. 2000 Mar 15;19(6):1187-94 [10716919.001]
  • [Cites] Blood. 2000 Jul 1;96(1):282-7 [10891463.001]
  • [Cites] Int J Cancer. 2002 Sep 1;101(1):86-94 [12209593.001]
  • [Cites] Mediators Inflamm. 2003 Jun;12(3):167-71 [12857600.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8345-50 [14678995.001]
  • [Cites] J Surg Res. 2004 Jan;116(1):165-71 [14732364.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1312-7 [15931265.001]
  • [Cites] Neoplasma. 2005;52(2):182-4 [15800718.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):14-7 [11815955.001]
  • [Cites] Angiogenesis. 2002;5(1-2):111-8 [12549868.001]
  • [Cites] Eur J Haematol. 2003 Jul;71(1):9-17 [12801293.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1159-65 [15130943.001]
  • (PMID = 23100932.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453162
  • [Keywords] NOTNLM ; AML / Angiogenesis / Endostatin / Prognosis
  •  go-up   go-down


33. Ma X, Chan EC: Fluorescence-based liver microsomal assay for screening of pharmaceutical reactive metabolites using a glutathione conjugated 96-well plate. Bioconjug Chem; 2010 Jan;21(1):46-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence-based liver microsomal assay for screening of pharmaceutical reactive metabolites using a glutathione conjugated 96-well plate.
  • The purpose of our paper is to develop and validate a fluorescence-based mouse liver microsomal (MLM) assay in screening pharmaceutical reactive metabolites (RMs) using a glutathione (GSH)-conjugated 96-well plate.
  • Poly(2-hydroxyethylmethacrylate) (pHEMA) polymeric membrane was coated on 96-well plates to provide a functional support for GSH conjugation.
  • The subsequent RM screening of a series of marketed drugs and chemical compounds resulted in a range of TI values (1.0-25.7%) that corroborated with their capacity in generating RMs.
  • The differences of TI values are statistically significant between the compounds which are known to produce RMs and those that do not generate reactive intermediates.
  • [MeSH-major] Biological Assay / methods. Drug Evaluation, Preclinical / methods. Glutathione / chemistry. Luminescent Measurements / methods. Microsomes, Liver / metabolism. Pharmaceutical Preparations / analysis. Pharmaceutical Preparations / metabolism

  • MedlinePlus Health Information. consumer health - Medicines.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957910.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Imines; 0 / Pharmaceutical Preparations; 362O9ITL9D / Acetaminophen; G6S9BN13TI / N-acetyl-4-benzoquinoneimine; GAN16C9B8O / Glutathione
  •  go-up   go-down


34. Hack CE, Haber LT, Maier A, Shulte P, Fowler B, Lotz WG, Savage RE Jr: A Bayesian network model for biomarker-based dose response. Risk Anal; 2010 Jul;30(7):1037-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A Bayesian network model was developed to integrate diverse types of data to conduct an exposure-dose-response assessment for benzene-induced acute myeloid leukemia (AML).
  • The network approach was used to evaluate and compare individual biomarkers and quantitatively link the biomarkers along the exposure-disease continuum.
  • The network-derived benchmark concentration was approximately an order of magnitude lower than that from the usual exposure concentration versus response approach, which suggests that the presence of more information in the low-dose region (where changes in biomarkers are detectable but effects on AML mortality are not) helps inform the description of the AML response at lower exposures.
  • This work provides a quantitative approach for linking changes in biomarkers of effect both to exposure information and to changes in disease response.
  • Such linkage can provide a scientifically valid point of departure that incorporates precursor dose-response information without being dependent on the difficult issue of a definition of adversity for precursors.
  • [MeSH-minor] Air Pollutants / toxicity. Dose-Response Relationship, Drug. Humans. Leukemia, Myeloid, Acute / chemically induced. Monte Carlo Method

  • Hazardous Substances Data Bank. BENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20412521.001).
  • [ISSN] 1539-6924
  • [Journal-full-title] Risk analysis : an official publication of the Society for Risk Analysis
  • [ISO-abbreviation] Risk Anal.
  • [Language] eng
  • [Grant] United States / PHS HHS / / GS-10F-0369N
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Biomarkers; J64922108F / Benzene
  •  go-up   go-down


35. Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol; 2005 Aug 20;23(24):5705-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
  • PURPOSE: Because both t(8;21) and inv(16) disrupt core binding factor (CBF) in acute myeloid leukemia (AML) and confer relatively favorable prognoses, these cytogenetic groups are often treated similarly.
  • PATIENTS AND METHODS: We analyzed 144 consecutive adults with t(8;21) and 168 with inv(16) treated on Cancer and Leukemia Group B front-line studies.
  • RESULTS: With a median follow-up of 6.4 years, for CBF AML as a whole, the CR rate was 88%, 5-year OS was 50% and CIR was 53%.
  • Unexpectedly, race was an important predictor for t(8;21) AML, in that nonwhites failed induction more often (odds ratio = 5.7; P = .006) and had shorter OS than whites when certain secondary cytogenetic abnormalities were present.
  • For inv(16) AML, secondary cytogenetic abnormalities (especially +22) and male sex predicted better outcome.
  • CONCLUSION: When the prognostic impact of race, secondary cytogenetic abnormalities, sex, and response to salvage treatment is considered, t(8;21) and inv(16) AMLs seem to be distinct clinical entities and should be stratified and reported separately.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / genetics
  • [MeSH-minor] Acute Disease. Aged. Aziridines / administration & dosage. Benzoquinones / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Proportional Hazards Models. Prospective Studies. Remission Induction. Statistics, Nonparametric. Survival Analysis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110030.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / K08-CA90469; United States / NCI NIH HHS / CA / P30-CA16058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aziridines; 0 / Benzoquinones; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FQL5EUP13W / diaziquone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


86. Kang LC, Dunphy CH: Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes. Arch Pathol Lab Med; 2006 Feb;130(2):153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
  • CONTEXT: MIC2 ("thymus leukemia") antigen has been shown to be expressed by T cells and monocytes, as well as B cells and granulocyte-lineage cells.
  • It is most intensely expressed by the most immature thymus T-lineage cells and is more intensely expressed by CD34-positive/CD33-positive myeloid cells (compared to more mature myeloid cells) and the earliest CD34-positive/CD10-positive B-cell precursor cells (compared to cells of later B-cell precursor stages).
  • CD99 (MIC2) is characteristically expressed in precursor B- and T-cell lymphoblastic lymphomas/leukemias, as well as in Ewing sarcoma/primitive neuroectodermal tumors (ES/PNET).
  • It has also been shown to be expressed in a few terminal deoxynucleotidyl transferase (TdT)-positive myeloid processes, but has been uniformly negative in TdT-negative myeloid processes.
  • A more recent study showed that 43% of acute myeloid leukemias (AMLs) and 55% of chloromas express CD99, concluding that CD99 is commonly expressed in AML and rarely seen in myeloproliferative disorders, myelodysplastic syndromes, or normal bone marrow.
  • Although this study speculated that MIC2 expression was probably not limited to TdT-positive AML, there was no comparison with TdT reactivity in this study.
  • OBJECTIVE: Since AML and high-grade myelodysplastic syndrome may occasionally be difficult to distinguish morphologically from acute lymphoblastic leukemia and ES/ PNET, we undertook a study to analyze MIC2 expression in conjunction with TdT reactivity in distinguishing AML or high-grade myelodysplastic syndrome from acute lymphoblastic leukemia and ES/PNET.
  • DESIGN: We studied bone marrow core and clot paraffin specimens from AML (classified according to criteria of the World Health Organization; n = 49), myelodysplastic syndromes (n = 4), precursor B-cell acute lymphoblastic leukemia (n = 4), ES/PNET (n = 1), and normal bone marrow (n = 3) with MIC2 (CD99) and TdT immunohistochemistry.
  • RESULTS: Overall, CD99 was expressed in 24 (49%) of 49 AML cases, including all (11/11) TdT-positive cases.
  • CD99 was expressed in all subtypes of AML except M5.
  • Expression of TdT was limited to a subset of AML-M0, -M1, -M2, and -M4, and AML with multilineage dysplasia.
  • CONCLUSIONS: In contrast to a previous study, CD99 expression was not restricted to TdT-positive hematologic proliferations.
  • In particular, the CD99-positive M3 and M7 AMLs were TdT negative.
  • An M5 AML may likely be excluded based on a uniform TdT-negative/CD99-negative immunophenotype.
  • [MeSH-major] Antigens, CD / metabolism. Bone Marrow / metabolism. Cell Adhesion Molecules / metabolism. DNA Nucleotidylexotransferase / metabolism. Leukemia, Myeloid, Acute / metabolism. Myelodysplastic Syndromes / metabolism
  • [MeSH-minor] Diagnosis, Differential. Flow Cytometry. Humans. Immunohistochemistry. Neuroectodermal Tumors, Primitive / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retrospective Studies. Sarcoma, Ewing / diagnosis

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454553.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  •  go-up   go-down


87. Yoneda K, Morii T, Nieda M, Tsukaguchi N, Amano I, Tanaka H, Yagi H, Narita N, Kimura H: The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy. Leuk Res; 2005 Feb;29(2):147-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy.
  • In this study, we assessed the Valpha24+ NKT cell numbers in peripheral blood (PB) from 30 healthy donors and 70 patients with haematopoietic malignancy including chronic myelogenous leukemia (CML), malignant lymphoma (ML), acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
  • Here, we demonstrated that PB Valpha24+ NKT cell numbers were significantly decreased in all the patients with haematopoietic malignancy in comparison with that in healthy donors (P < 0.005).
  • In particular CD4- CD8- Valpha24+ NKT cell numbers were more significantly decreased in the patients with haematopoietic malignancy (P < 0.0001).
  • [MeSH-major] Hematologic Neoplasms / blood. Killer Cells, Natural / cytology. Receptors, Antigen, T-Cell, alpha-beta / biosynthesis
  • [MeSH-minor] Antigens, CD4 / biosynthesis. Antigens, CD8 / biosynthesis. Flow Cytometry. Humans. Lymphocyte Count. Lymphocytes / cytology. Lymphocytes / immunology. Survival Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607362.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Receptors, Antigen, T-Cell, alpha-beta
  •  go-up   go-down


88. Müller AM, Duque J, Shizuru JA, Lübbert M: Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene; 2008 Oct 2;27(44):5759-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complementing mutations in core binding factor leukemias: from mouse models to clinical applications.
  • A great proportion of acute myeloid leukemias (AMLs) display cytogenetic abnormalities including chromosomal aberrations and/or submicroscopic mutations.
  • These abnormalities significantly influence the prognosis of the disease.
  • Core binding factor (CBF) leukemias denote AMLs with chromosomal aberrations disrupting one of the CBF transcription factor genes; the most common examples are translocation t(8;21) and inversion inv(16), which result in the generation of the AML1-ETO and CBFbeta-MYH11 fusion proteins, respectively.
  • However, in murine models, these alterations alone do not suffice to generate full-blown leukemia, but rather, complementary events are required.
  • In fact, a substantial proportion of primary CBF leukemias display additional activating mutations, mostly of the receptor tyrosine kinase (RTK) c-KIT.
  • Here, we present a concise review on complementing mutations in CBF leukemias including pathophysiology, mouse models, and clinical implications.
  • [MeSH-major] Chromosome Aberrations. Core Binding Factors / genetics. Leukemia, Myeloid, Acute / diagnosis. Mutation. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Animals. Disease Models, Animal. Genetic Complementation Test. Mice. Prognosis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604246.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factors; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 118
  •  go-up   go-down


89. Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bolaños-Meade J, Greer JM, Carraway HE, Gore SD, Jones RJ, Levis MJ, McDevitt MA, Doyle LA, Wright JJ: Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res; 2010 Jul;34(7):877-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
  • In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features.
  • Median OS and DFS are not reached (67% alive 12.5-31 months, 58% in CR 11.4-30 months), with median follow-up 22 months.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1235-48 [19776405.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4063-73 [19144992.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):376-87 [10699068.001]
  • [Cites] Cell Death Differ. 2001 Jul;8(7):715-24 [11464216.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31793-9 [11431468.001]
  • [Cites] Genome Biol. 2001;2(10):RESEARCH0041 [11597333.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3527-38 [12429644.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Leuk Res. 2003 Apr;27(4):313-21 [12531222.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):307-15 [12538483.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1822-33 [12702569.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Am J Med. 1969 Sep;47(3):351-66 [5258033.001]
  • [Cites] Ann Intern Med. 1975 Jan;82(1):54-7 [16553.001]
  • [Cites] Medicine (Baltimore). 1980 Nov;59(6):409-25 [7003298.001]
  • [Cites] Blood. 1989 Oct;74(5):1499-506 [2676014.001]
  • [Cites] Biochem Pharmacol. 1993 Nov 17;46(10):1831-40 [8250970.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2973-8 [8674031.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4856-61 [8895733.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3375-80 [9269999.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4634-41 [10493518.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8403-12 [16322302.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):138-48 [16432172.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):697-706 [16690529.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1810-6 [17095617.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-73 [17671131.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2637-45 [18981292.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4052-62 [19144991.001]
  • [CommentIn] Leuk Res. 2010 Jul;34(7):856-7 [20378170.001]
  • (PMID = 19962759.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P30 CA06973-44; United States / NCI NIH HHS / CA / U01 CA069854; United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / CA069854-05; United States / NCI NIH HHS / CA / U01 CA070095; United States / NCRR NIH HHS / RR / M01 RR000052; United States / NCI NIH HHS / CA / U01 CA069854-05
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 0 / Polyamines; 04079A1RDZ / Cytarabine; 45AD6X575G / alvocidib; 63CZ7GJN5I / Allopurinol; 9YCX42I8IU / Sevelamer; BZ114NVM5P / Mitoxantrone
  • [Other-IDs] NLM/ NIHMS158765; NLM/ PMC2875369
  •  go-up   go-down


90. Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, Hanada R, Hamamoto K, Kobayashi R, Morimoto A, Nakayama H, Tsuchida M, Horibe K, Kigasawa H, Tsukimoto I, Japanese Childhood AML Cooperative Study Group: Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. J Clin Oncol; 2007 Dec 1;25(34):5442-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
  • PURPOSE: To evaluate a less intensive chemotherapeutic regimen specifically designed for patients with Down syndrome (DS) and acute myeloid leukemia (AML), and to determine the prognostic factors for event-free survival.
  • PATIENTS AND METHODS: Seventy-two patients with AML-DS were treated with remission induction chemotherapy consisting of pirarubicin (25 mg/m2/d for 2 days), cytarabine (100 mg/m2/d for 7 days), and etoposide (150 mg/m2/d for 3 days).
  • Prophylaxis for CNS leukemia was not included.
  • RESULTS: All but two patients were younger than 4 years, and 67 of the 72 patients (93%) were diagnosed as acute megakaryoblastic leukemia (AMKL).
  • CONCLUSION: A less intensive chemotherapeutic regimen produces excellent outcomes in standard-risk AML-DS patient.
  • Risk-oriented therapy should be considered for future trials in AML-DS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Down Syndrome / complications. Leukemia, Megakaryoblastic, Acute / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Infant. Male. Prospective Studies. Treatment Outcome


91. Slovak ML, Smith DD, Bedell V, Hsu YH, O'Donnell M, Forman SJ, Gaal K, McDaniel L, Schultz R, Ballif BC, Shaffer LG: Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes. Mol Cytogenet; 2010;3:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We performed an exploratory study on 30 cases of MDS, myeloproliferative neoplasia (MPN) or evolving acute myeloid leukemia (AML) (% bone marrow blasts ≤ 30%, range 0-30%, median, 8%) by aCGH, using a genome-wide bacterial artificial chromosome (BAC) microarray.
  • Cryptic 344-kb RUNX1 deletions were found in three patients at time of AML transformation.
  • CONCLUSIONS: The detection of previously known and unknown genomic alterations suggests that aCGH has considerable promise for identification of both recurring microscopic and submicroscopic genomic imbalances that contribute to myeloid disease pathogenesis and progression.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21078186.001).
  • [ISSN] 1755-8166
  • [Journal-full-title] Molecular cytogenetics
  • [ISO-abbreviation] Mol Cytogenet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3000833
  •  go-up   go-down


92. Fuchs O: Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr Mol Pharmacol; 2010 Nov;3(3):98-122
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nuclear factor-kappaB (NF-κB) upregulates the transcription of proteins that promote cell survival, stimulate growth, induce angiogenesis and reduce susceptibility to apoptosis.
  • NF-κB signaling pathway is constitutively activated in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), lymphomas and in multiple myeloma (MM).
  • Triptolide (diterpenoid triepoxyde), a purified component of a traditional Chinese medicine, extracted from a shrub-like vine named Trypterygium wilfordii Hook F (TWHF) inhibits transcriptional activation of NF-κB and downregulates the expression of various NF-κB-regulated genes.
  • Triptolide (10-80 ng/ml) induces apoptosis of MM cells and effectively inhibits cell growth of MM cells.
  • LC-1, the dimethylamino-parthenolide (DMAPT) derivative demonstrated significant cytotoxicity to AML blasts targeting NF-κB.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20594187.001).
  • [ISSN] 1874-4702
  • [Journal-full-title] Current molecular pharmacology
  • [ISO-abbreviation] Curr Mol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diterpenes; 0 / Epoxy Compounds; 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Phenanthrenes; 0 / Proteasome Inhibitors; 139874-52-5 / NF-kappaB inhibitor alpha; 19ALD1S53J / triptolide; 2M36281008 / Etodolac; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


93. Birtwistle J, Hayden RE, Khanim FL, Green RM, Pearce C, Davies NJ, Wake N, Schrewe H, Ride JP, Chipman JK, Bunce CM: The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutat Res; 2009 Mar 9;662(1-2):67-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
  • Other studies have demonstrated the oxidative activation of polycyclic aromatic hydrocarbon (PAH) procarcinogens by AKR1C3 in cell-free systems.
  • Quantitative RT-PCR identified AKR1C3 as the predominant AKR1C isoform expressed in acute myeloid leukemia (AML).
  • Exposure of K562 and KG1a myeloid cell lines to the known AKR1C3 substrate 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol (7,12-DMBA-3,4-diol) resulted in both single strand DNA breaks and oxidative DNA damage as measured using conventional and FPG-modified comet assays respectively.
  • Knockdown of AKR1C3 did not alter single strand DNA breaks following 7,12-DMBA-3,4-diol exposure but significantly decreased oxidative DNA damage.
  • A similar interrelationship between AKR1C3 activity and 7,12-DMBA-3,4-diol mediated oxidative DNA damage but not single strand breaks was observed in KG1a cells.
  • Since K562 cells are a model of AML blast crisis of chronic myeloid leukemia (CML) the data presented here identify AKR1C3 as a novel mediator of carcinogen-induced initiation of leukemia, as a novel regulator of erythroid differentiation and paradoxically as a potential new target in the treatment of CML.
  • [MeSH-major] 3-Hydroxysteroid Dehydrogenases / metabolism. 9,10-Dimethyl-1,2-benzanthracene / analogs & derivatives. DNA Damage. Hydroxyprostaglandin Dehydrogenases / metabolism. Leukemia, Myeloid, Acute / enzymology. Oxidative Stress
  • [MeSH-minor] Cell Differentiation. Cell Line, Tumor. Gene Expression Regulation, Leukemic. Gene Knockdown Techniques. Glycophorin / metabolism. Hemoglobins / metabolism. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Stem Cells / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19162045.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glycophorin; 0 / Hemoglobins; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 72617-60-8 / 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases; EC 1.1.1.- / AKR1C3 protein, human; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases
  •  go-up   go-down


94. Tohyama K, Shiga S, Itose Y, Uchihashi K, Ohkura M, Takahashi K, Itoh M, Ichiyama S, Hamaguchi Y: Improved detection of minimal acute myeloid leukemia cells by the use of the combined parameters of XE-2100 hematology analyzer. Cytometry B Clin Cytom; 2005 Jul;66(1):18-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved detection of minimal acute myeloid leukemia cells by the use of the combined parameters of XE-2100 hematology analyzer.
  • BACKGROUND: For the diagnosis and therapy of acute leukemia, it is important to detect a small number of leukemic cells precisely.
  • Although several automated hematology analyzers that carry blast-detecting programs have been developed, they do not exert sufficient detection sensitivity to exceed the sensitivity of manual eye counting method.
  • A small number of leukemic myeloblasts was detected at the better sensitivity than the eye counting method in the clinical course of the patients with acute myeloid leukemia.
  • CONCLUSIONS: The daily practical use of this blast multi-scoring program will surely contribute to sensitive, objective, and real-time evaluation of the control of acute myeloid leukemia with a low cost.
  • [MeSH-major] Hematologic Tests / methods. Hematology / methods. Leukemia, Myeloid / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Child, Preschool. Erythrocyte Count / instrumentation. Erythrocyte Count / methods. Female. Humans. Leukocyte Count / instrumentation. Leukocyte Count / methods. Male. Middle Aged. Platelet Count / instrumentation. Platelet Count / methods. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15800879.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Fatih T, Selim Y, Mesut A, Demirel YN, Yuksel P: An unusual cause of unilateral pleural effusion in the setting of aortic stenosis: acute myeloid leukemia. Intern Med; 2007;46(6):325-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual cause of unilateral pleural effusion in the setting of aortic stenosis: acute myeloid leukemia.
  • Examination of the pleural fluid revealed myeloid blasts.
  • Bone marrow aspiration smear and flow cytometric analysis of the bone marrow and pleural fluid were consistent with acute myeloid leukemia.
  • [MeSH-major] Aortic Valve Stenosis / complications. Leukemia, Myeloid / complications. Pleural Effusion / etiology
  • [MeSH-minor] Acute Disease. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / therapeutic use. Fatal Outcome. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Liver Diseases / complications. Liver Diseases / diagnosis. Liver Diseases / therapy. Male. Middle Aged. Mycoses / complications. Mycoses / diagnosis. Mycoses / therapy. Treatment Outcome. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380003.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; FLAG protocol
  •  go-up   go-down


96. Bayona C, Lassaletta A, Pérez A, Sevilla J, Albi G, Villa JR, Madero L: [Fatal hemoptysis secondary to invasive pulmonary aspergillosis in a girl with acute myeloblastic leukemia]. An Pediatr (Barc); 2007 Sep;67(3):278-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fatal hemoptysis secondary to invasive pulmonary aspergillosis in a girl with acute myeloblastic leukemia].
  • [Transliterated title] Hemoptisis fatal secundaria a aspergilosis pulmonar invasiva en una paciente con leucemia mieloblástica aguda.
  • [MeSH-major] Aspergillosis / complications. Hemoptysis / etiology. Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / complications

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785168.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


97. Suzukawa K, Shimizu S, Nemoto N, Takei N, Taki T, Nagasawa T: Identification of a chromosomal breakpoint and detection of a novel form of an MLL-AF17 fusion transcript in acute monocytic leukemia with t(11;17)(q23;q21). Int J Hematol; 2005 Jul;82(1):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a chromosomal breakpoint and detection of a novel form of an MLL-AF17 fusion transcript in acute monocytic leukemia with t(11;17)(q23;q21).
  • More than 40 genes have been reported as translocation partners of the mixed lineage leukemia gene (MLL) in hematologic malignancies.
  • On the other hand, there is only 1 report of an MLL-AF17 fusion transcript in acute myeloid leukemia (AML).
  • Here we describe a 40-year-old man with a diagnosis of AML involving t(11;17)(q23;q21).
  • Although the previously reported form of the MLL-AF17 fusion transcript was not detected by reverse transcriptase-polymerase chain reaction (PCR) analysis, a novel form of an MLL-AF17 fusion transcript joining MLL exon 6 to AF17 exon 9 was detected by complementary DNA panhandle PCR.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 17. DNA-Binding Proteins / genetics. Leukemia, Monocytic, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic / genetics. Chromosome Breakage. Histone-Lysine N-Methyltransferase. Humans. Leucine Zippers. Male. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2003 Aug;4(2):99-110 [12957285.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14 ):4075-80 [12124344.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):333-7 [11809673.001]
  • [Cites] Nucleic Acids Res. 1988 Jun 24;16(12):5533-56 [2838820.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Aug;145(1):54-9 [12885463.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4261-5 [10485469.001]
  • [Cites] Oncogene. 2003 Jan 9;22(1):157-60 [12527918.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8107-11 [8058765.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):197-207 [14522254.001]
  • [Cites] Leukemia. 2002 Oct;16(10):1927-32 [12357344.001]
  • [Cites] Cancer Genet Cytogenet. 1994 May;74(1):50-3 [8194047.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9597-602 [10920186.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):178-9 [14734237.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):33-7 [11782354.001]
  • (PMID = 16105757.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / MLL-AF17 fusion protein, human; 0 / MLLT6 protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


98. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ: Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer; 2007 Mar 15;109(6):1152-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.
  • BACKGROUND: CXC chemokine receptor 4 (CXCR4) expression in acute myeloid leukemia (AML) is reported to correlate with FLT3 gene mutation and poorer prognosis.
  • The prognostic significance of CXCR4 expression in patients with AML that have a normal karyotype and no evidence of FLT3 gene mutations was examined.
  • METHODS: The prognostic significance of CXCR4 expression in 122 AML patients with normal karyotype and no evidence of FLT3 gene mutation treated at our institution between 1997 and 2003 was analyzed.
  • Sixty-six patients died, including 9 with no evidence of disease.
  • CONCLUSIONS.: The results suggest that CXCR4 expression is associated with poor prognosis in AML patients with an unmutated FLT3 gene.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Receptors, CXCR4 / analysis. Receptors, CXCR4 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Immunohistochemistry. Karyotyping. Male. Middle Aged. Mutation. Prognosis. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315232.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, CXCR4; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


99. Chen HC, Hu WX, Liu QX, Li WK, Chen FZ, Rao ZZ, Liu XF, Luo YP, Cao YF: Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility. Eur J Cancer Prev; 2008 Jun;17(3):251-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility.
  • The genetic polymorphisms of biotransformation phase I enzymes, cytochrome P450 (CYP1A1 and CYP2D6), and phase II enzymes, glutathione S-transferase (GSTM1 and GSTT1), were analyzed in 204 healthy persons and 348 leukemia patients, who suffered from also acute lymphoblastic leukemia (ALL), acute nonlymphoblastic leukemia (ANLL) chronic myelogenous leukemia (CML), from the Han ethnic group in Changsha City of Hunan Province of China.
  • Our results showed that the frequencies of polymorphisms of CYP1A1, CYP2D6 and GSTT1 among the groups including acute lymphoblastic leukemia, ANLL, chronic myelogenous leukemia and healthy control have no significant differences.
  • The variation of GSTM1-null genotype alone correlated with the development of ANLL.
  • The combined genotypes of GSTM1-null with GSTT1-null, or GSTM1-null with CYP1A1 heterozygous mutant, or GSTM1-null with CYP1A1 heterozygous mutant and CYP2D6 heterozygous mutant, or GSTM1-null with CYP1A1 heterozygous mutant, CYP2D6 heterozygous mutant and GSTT1-null were found in individuals with high risk of ANLL.
  • All these findings suggest that GSTM1-null genotype alone or in coordination with the relevant genotypes of other metabolic enzymes might be susceptibility factors in the etiology of ANLL.
  • [MeSH-major] Cytochrome P-450 CYP1A1 / genetics. Cytochrome P-450 CYP2D6 / genetics. Glutathione Transferase / genetics. Leukemia / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Case-Control Studies. DNA Mutational Analysis. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414197.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP2D6; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


100. Advances in the biology and therapy of acute myelogenous leukemia. Selection of keynote addresses from the Acute Leukemia Forum 2007. March 23, 2007. San Francisco, California, USA. Best Pract Res Clin Haematol; 2008 Mar;21(1):1-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the biology and therapy of acute myelogenous leukemia. Selection of keynote addresses from the Acute Leukemia Forum 2007. March 23, 2007. San Francisco, California, USA.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561374.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Congresses; Overall
  • [Publication-country] England
  •  go-up   go-down






Advertisement